This is an essential observation, as IL-17A was previously shown to exacerbate inflammation in IBD, whereas IL-22-secreting ILC3s have been described to be beneficial for IBD patients, leukemic patients after HSCT, and GI tract transplant recipients (15, 21, 25, 27, 48–50). Here, IL22 is linked to inflammatory bowel disease.